Susie Lisa
Senior Vice President of Investor Relations
Nice. Good night, everybody. My title is Susie Lisa, and because the Senior Vice President of Investor Relations at Vertex Prescription drugs. I am actually thrilled that you might all be right here with us tonight in Houston and for these of you on the road as nicely becoming a member of us for the American Society of Nephrology Kidney Week 2025 and for a broad replace on the Vertex Kidney applications.
I am going to run by way of the agenda briefly. Our CEO, Dr. Reshma Kewalramani will open with an outline of our 3 kidney applications in pivotal improvement and 1 presently in a proof-of-concept examine. Following Reshma’s remarks, Vertex is extraordinarily happy and grateful to have 3 doctor thought leaders right here for you tonight to share their views on the RUBY-3, IgAN and pMN knowledge offered earlier this night, the RAINIER Section III examine of IgAN, of Pove and IgAN, which not too long ago accomplished full enrollment in file time and the outlook for tips in treating sufferers with critical kidney ailments like IgAN.
First, we’ve got the pleasure of listening to from Dr. James A. Tumlin, Professor of Medication in Nephrology at Emory College College of Medication, Director of Analysis at Georgia Nephrology and President of NephroNet. Dr. Tumlin will present a recap of his late breaker presentation of the RUBY-3 knowledge in IgAN